A Placebo-Controlled, Double-Blind Study of the Efficacy and Safety of Aripiprazole in Patients With Acute Bipolar Mania

McElroy SL, Keck PE: Pharmacologic agents for the treatment of acute bipolar mania. Biol Psychiatry 2000; 48:539–557

Garfinkel PE, Stancer HC, Persad E: A comparison of haloperidol, lithium carbonate, and their combination in the treatment of mania. J Affect Disord 1980; 2:279–288

Prien RF, Caffey EM Jr, Klett CJ: Comparison of lithium carbonate and chlorpromazine in the treatment of mania: report of the Veterans Administration and National Institute of Mental Health Collaborative Study Group. Arch Gen Psychiatry 1972; 26:146–153

Vestergarrd P: Treatment and prevention of mania: a Scandinavian perspective. Neuropsychopharmacology 1992; 7:249–259

Tohen M, Zhang F, Taylor CC, Burns P, Zarate C, Sanger T, Tollefson G: A meta-analysis of the use of typical antipsychotic agents in bipolar disorder. J Affect Disord 2001; 65:85–93

Allison DB, Casey DE: Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 2001; 62:22–31

Turrone P, Kapur S, Seeman MV, Flint AJ: Elevation of prolactin levels by atypical antipsychotics. Am J Psychiatry 2002; 159:133–135

Glassman AH, Bigger JT Jr: Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001; 158:1774–1782

Koro CE, Fedder DO, L’Italien GJ, Weiss SS, Magder LS, Kreyenbuhl J, Revicki DA, Buchanan RW: An assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control. Br Med J 2002; 325:243

Henderson DC: Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence? CNS Drugs 2002; 16:77–89

Meyer JM: Novel antipsychotics and severe hyperlipidemia. J Clin Psychopharmacol 2001; 21:369–374

Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, Yocca FD, Molinoff PB: Aripiprazole, a novel antipsychotic, is a high affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002; 302:381–389

Inoue T, Domae M, Yamada K, Furukawa T: Effects of the novel antipsychotic agent 7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland. J Pharmacol Exp Ther 1996; 277:137–143

Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA: The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 2002; 441:137–140

Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, Saha A, Ali M, Iwamoto T: Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term placebo-controlled trials. Schizophr Res 2003; 61:123–136

Young RC, Biggs JT, Ziegler VE, Meyer DA: A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978; 133:429–435

Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W: Modification of the Clinical Global Impressions (CGI) scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res 1997; 73:159–171

Simpson GM, Angus JWS: A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212:11–19

Barnes TRE: A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154:672–676

Tohen M, Sanger TM, McElroy SL, Tollefson GD, Chengappa KNR, Daniel DG, Petty F, Centorrino F, Wang R, Grundy SL, Greaney MG, Jacobs TG, David SR, Toma V (Olanzapine HGEH Study Group): Olanzapine versus placebo in the treatment of acute mania. Am J Psychiatry 1999; 156:702–709

Tohen M, Jacobs TG, Grundy SL, McElroy SL, Banov MC, Janicak PG, Sanger T, Risser R, Zhang F, Toma V, Francis J, Tollefson GD, Breier A (Olanzapine HGEH Study Group): Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. Arch Gen Psychiatry 2000; 57:841–849

Keck PE Jr, Versiani M, Potkin S, West SA, Giller E, Ice K (Ziprasidone in Mania Study Group): Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry 2003; 160:741–748

McElroy SL, Frye MA, Suppes T, Dhavale D, Keck PE, Leverich GS, Altshuler L, Denicoff KD, Nolen WA, Kupka R, Grunze H, Walden J, Post RM: Correlates of overweight and obesity in 644 patients with bipolar disorder. J Clin Psychiatry 2002; 63:207–213

Sanger TM, Grundy SL, Gibson PJ, Namjoshi MA, Greaney MG, Tohen MF: Long-term olanzapine therapy in the treatment of bipolar I disorder: an open-label continuation phase study. J Clin Psychiatry 2001; 62:273–281

Elmslie JL, Silverstone JT, Mann JI, Williams SM, Romans SE: Prevalence of overweight and obesity in bipolar patients. J Clin Psychiatry 2000; 61:179–184

Fagiolini A, Frank E, Houck PR, Mallinger A, Swartz H, Buysse DJ, Ombao H, Kupfer DJ: Prevalence of obesity and weight change during treatment in patients with bipolar I disorder. J Clin Psychiatry 2002; 63:528–533

Carlsson A, Waters N, Waters S, Carlsson ML: Network interactions in schizophrenia—therapeutic implications. Brain Res Rev 2000; 31:342–349

Stahl SM: Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1: “Goldilocks” actions at dopamine receptors. J Clin Psychiatry 2001; 62:841–842

Stahl SM: Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2: illustrating their mechanism of action. J Clin Psychiatry 2001; 62:923–924

Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW: Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002; 63:763–771